Ironwood Pharmaceuticals
IRWD
3.75
+0.12
+3.31%
Ironwood Pharmaceuticals
US · IRWD
#3609 by market cap
3.75
+0.12
+3.31%
Live - 5344 symbols - heartbeat 319s ago
· 2026-10-08 08:58
Pre-market
3.80
+1.27%
After-hours
3.54
-5.59%
Overnight
3.72
-0.80%
- Market cap
- 619.65M
- P/E (TTM)i
- 4.75
- P/Bi
- -3.83
- EPSi
- 0.15
- Div yieldi
- 0.00%
- 52W posi
- 54%
Reader sentiment
Are you bullish or bearish on IRWD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 1.2 percentage points.
Institutional ownership
- Held by institutions
- 99.00% -1.17pp
- Institutions
- 260
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund58.67%
Hedge Fund29.20%
Public Company8.71%
Individual/Insider3.24%
Private Company0.83%
Government Pension Fund0.74%
Bank/Investment Bank0.31%
Family Office/Trust0.23%
Insurance Company0.19%
Top holders as of 2026-06-30
BlackRock
10.77% · 17.79M sh
Armistice Capital LLC
8.43% · 13.93M sh
Sarissa Capital Management LP
5.56% · 9.19M sh
State Street Global Advisors
5.33% · 8.81M sh
Bank of America Corporation
5.26% · 8.68M sh
Renaissance Technologies Corp.
4.84% · 7.99M sh
Vanguard Capital Management, LLC
4.63% · 7.65M sh
AQR Capital Management
3.81% · 6.29M sh
Acadian Asset Management LLC
3.54% · 5.85M sh
Vanguard Portfolio Management, LLC
3.34% · 5.51M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 29 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| Thomas McCourt | Chief Executive Officer | 1.04% |
| Mark Currie | Director | 0.41% |
| Michael Shetzline | Chief Medical Officer, Senior VP and Head of Research & Drug Development | 0.23% |
| Alexander Denner | Independent Director | 0.20% |
| Jon Duane | Independent Director | 0.15% |
| Julie McHugh | Executive Chairperson | 0.15% |
| Tammi Gaskins | Senior Vice President & Chief Commercial Officer. | 0.14% |
| Jay Shepard | Director | 0.14% |
| Marla Kessler | Independent Director | 0.14% |
| John Minardo | Chief Legal Officer | 0.14% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-23 | Michael Shetzline | Chief Medical Officer, Senior VP and Head of Research & Drug Development | Intent to Sell (Form 144) | -83,306 | $4.53 |
| 2026-09-14 | Alexander Denner | Independent Director | Other Acquisition | +3,694 | -- |
| 2026-07-19 | Jeffrey Silber | Chief Medical Officer, Head of Research & Drug Development | Other Acquisition | +137,036 | -- |
| 2026-07-06 | Ronald Silver | Corporate Controller & Principal Accounting Officer | Automatic Disposition | -127,890 | $4.52 |
| 2026-06-15 | Jay Shepard | Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Alexander Denner | Independent Director | Other Acquisition | +67,546 | -- |
| 2026-06-15 | Mark Currie | Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Catherine Moukheibir | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Julie McHugh | Executive Chairperson | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Julie McHugh | Executive Chairperson | Automatic Disposition | -21,571 | $3.73 |
| 2026-06-15 | Marla Kessler | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Jon Duane | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-05-18 | Ronald Silver | Corporate Controller & Principal Accounting Officer | Other Acquisition | +25,000 | -- |
| 2026-03-16 | Sarissa Capital Management LP | -- | Open Market Disposition | -6,730,800 | $3.05–3.31 |
| 2026-03-12 | Alexander Denner | Independent Director | Other Acquisition | +4,451 | -- |
| 2026-03-09 | Thomas McCourt | Chief Executive Officer | Other Acquisition | +409,836 | -- |
| 2026-03-09 | Michael Shetzline | Chief Medical Officer, Senior VP and Head of Research & Drug Development | Other Acquisition | +136,612 | -- |
| 2026-03-09 | Ronald Silver | Corporate Controller & Principal Accounting Officer | Other Acquisition | +163,934 | -- |
| 2026-03-09 | John Minardo | Chief Legal Officer | Other Acquisition | +136,612 | -- |
| 2026-03-09 | Gregory Martini | Vice President of Strategic Finance & Investor Relations | Other Acquisition | +136,612 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:58:11 · For reference only, not investment advice and not tailored to your situation.